Structure Therapeutics

CompanyUnited States

Structure Therapeutics develops one asset, in phase 2 (aleniglipron in obesity). Mostly small molecule acting on Insulin/IGF-1 signalling and GLP1R; based in the United States.

1
Asset
Furthest stage: Phase 2; 0
Trials: 2
Signals

Pipeline

1

aleniglipron
Activates GLP-1 receptors to reduce appetite and promote weight loss.
Phase 2, Small molecule, Insulin/IGF-1 signalling, GLP1R, obesity, obesity, overweight, or chronic weight management

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms3
Signals6
Similar companies6

Papers

Safety, Tolerability, and Efficacy of Aleniglipron in Doses up to 240 mg in People Living with Obesity: The Phase 2 ACCESS II Trial
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
Comparative Efficacy and Tolerability of Incretin-Based Medication for Weight Loss in Adults with Overweight or Obesity: A Meta-Analysis of Randomized Controlled Trials
ADA Scientific Sessions 2026 abstract, 5 Jun 2026
ACCESS Trial: Dose-Ranging Evaluation of Aleniglipron, an Oral Small Molecule Nonpeptide GLP-1RA, Demonstrates Meaningful Weight Reductions in People Living with Obesity and Overweight
ADA Scientific Sessions 2026 abstract, 5 Jun 2026